Autopsy report · NCT00422877

Taxoprexin® Treatment for Advanced Primary Cancers of the Liver, Gallbladder or Biliary Tract

“Sponsor suspended development of the drug on September 3, 2008.”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 1 year 2 months before it stopped.
• 13 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

American Regent, Inc.

Sponsor type

Industry

Conditions

Cancer of the Liver

Interventions

Taxoprexin

Participants

13

Sites

1

Countries

United States

Trials that died the same way

• Azacitidine and Lintuzumab in Treating Patients With Previously Untreated Myelodysplastic Syndromes
  “Drug no longer being supplied by sponsor” (70% match in meaning)
• Investigation of Femoropopliteal In Situ Valve Formation With the InterVene System
  “Project suspended by sponsor” (69% match in meaning)
• A Study of the Safety and Pharmacokinetics of AGS-8M4 Given in Combination With Chemotherapy in Women With Ovarian Cancer
  “Trial was terminated to allow sponsors to evaluate the future development of the drug program” (69% match in meaning)
• A Clinical Trial of YH1177 in Patients With Otitis Media and Otorrhea
  “Sponsor's decision for the Drug Development.” (69% match in meaning)
• Evaluation of Apricoxib (Selective Cyclooxygenase 2 Inhibition) in Modulating T Regulatory Cells of Patients With Early Stage Non-small Cell Lung Cancer
  “Drug sponsor stopped drug manufacture due to toxicity issues from other studies” (68% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.